Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S
Institut für Pathologie, Technische Universität München.
Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, Technische Universität München.
Aktuelle Urol. 2016 Dec;47(6):475-479. doi: 10.1055/s-0042-115401. Epub 2016 Dec 22.
c-Met plays a significant role in multiple cellular processes. Being encoded by a proto-oncogene, tyrosine kinase supports aggressive tumour behaviour such as tumour invasiveness and formation of metastases. For some subtypes of renal cell carcinoma studies have shown a association between c-Met expression and clinical outcome or prognosis. Therefore, c-Met represents a prognostic marker in renal cell carcinoma.Furthermore, c-MET will play a decisive role as a possible target for targeted therapies in the era of personalised medicine. Especially for RCC, the dual inhibition of VEGF and c-MET tyrosine kinase in cases of metastatic, treatment-resistant tumours is gaining clinical relevance. The role of c-Met has not been fully elucidated for all subtypes of renal cell carcinomas. The relevance of c-Met for the remaining subtypes of renal tumours has yet to be clarified.
c-Met在多种细胞过程中发挥着重要作用。作为一种原癌基因编码的酪氨酸激酶，它支持侵袭性肿瘤行为，如肿瘤侵袭和转移形成。对于某些肾细胞癌亚型的研究表明，c-Met表达与临床结果或预后之间存在关联。因此，c-Met是肾细胞癌的一个预后标志物。此外，在个性化医疗时代，c-MET作为靶向治疗的一个可能靶点将发挥决定性作用。特别是对于肾细胞癌，在转移性、治疗抵抗性肿瘤病例中对VEGF和c-MET酪氨酸激酶的双重抑制正变得具有临床意义。c-Met在所有肾细胞癌亚型中的作用尚未完全阐明。c-Met对其余肾肿瘤亚型的相关性还有待明确。
